Abstracts tagged "interferons"

Abstract Number: 1619 • 2014 ACR/ARHP Annual Meeting
Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs
David Drubin¹, Xiang Guo², Linglin Yang³, Rong Zeng³, Yuling Wu³, Mustimbo EliPollard Roberts³, Reynald Lescarbeau¹, Aaron Van Hooser¹, Michael Macoritto¹, Michelle Petri⁴ and Wendy White⁵, ¹Selventa, Cambridge, MA, ²Translational Sciences, MedImmune LLC, Gaithersburg, MD, ³MedImmune LLC, Gaithersburg, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose Interferons (IFNs) have long been implicated in the pathogenesis of systemic lupus erythematosus (SLE). However, the specific consequences of the IFN activity have not…
Abstract Number: 1613 • 2013 ACR/ARHP Annual Meeting
Anti-Malarial Drugs (hydroxychloroquine and quinacrine) Decrease The Production Of Interferon-Alfa Initiated By TLR-9 Agonist
Ou Jin¹, Xi Zhang¹, Qiuxia Li¹, Lingkai Fang¹, Hongyue Huang¹, Chengcheng Hou¹, Zetao Liao¹, Qiujing Wei¹, Zhiming Lin², Dongfang Lin¹ and Jieruo Gu³, ¹Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ²Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: Toll-like receptor 9 (TLR-9) plays an important role in initiating innate immunity. The recognition of self DNA fragments by TLR-9 may results in the…
Abstract Number: 1614 • 2013 ACR/ARHP Annual Meeting
Hydroxychloroquine Reverse The Elevation Of Interferon-Alfa Initiated By TLR-9 Agonist Which Irresponsive To Glucocorticoid
Ou Jin¹, Xi Zhang¹, Lingkai Fang¹, Qiuxia Li¹, Hongyue Huang¹, Zhiming Lin², Zetao Liao¹, Dongfang Lin¹, Chengcheng Hou¹ and Jieruo Gu³, ¹Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ²Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by chronic stimulation of the innate immune system by endogenous nucleic acids through toll-like receptors (TLRs) pathway, which…
Abstract Number: 1615 • 2013 ACR/ARHP Annual Meeting
Type I Interferons As a Serum Biomarker Of Subclinical Atherosclerosis In Pediatric Systemic Lupus Erythematosus Patients
Smriti Mohan¹, Julie Barsalou², Timothy J. Bradley³, Cameron Slorach³, Lawrence Ng⁴, Deborah M. Levy⁵, Earl D. Silverman² and Mariana J. Kaplan⁶, ¹Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁶Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder with a marked increase in cardiovascular (CV) morbidity and mortality due to premature atherosclerosis, distinct…
Abstract Number: 1616 • 2013 ACR/ARHP Annual Meeting
Interferon Regulatory Factors 3 and 5 As Key Elements Of The Interferon Signature On Plasmacytoid Dendritic Cells From Systemic Lupus Erythematosus Patients
Diana Gómez-Martín¹, Karina Santana-de Anda², Adriana Elizabeth Monsivais-Urenda³, Sandra Rajme-Lopez⁴, Luis Aparicio-Vera⁴, Jorge Alcocer-Varela¹ and Roberto González-Amaro³, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, ³Department of Immunology, Facultad de Medicina. UASLP, San Luis Potosí, Mexico, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico
Background/Purpose: Plasmacytoid dendritic cells (pDC) are considered the main source of type-I interferon (IFN-I). The interferon signature has been widely associated to systemic lupus erythematosus…
Abstract Number: 1572 • 2013 ACR/ARHP Annual Meeting
High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease
Kyriakos A. Kirou¹, Mikhail Olferiev¹, Elzbieta E. Jacek¹, Mari Lliguicota¹, Margaret Robotham¹, Wei-Ti Huang², Elena Gkrouzman¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) is elevated in many patients with SLE and is associated with more severe disease. However, the relationship between elevated levels…
Abstract Number: 1145 • 2013 ACR/ARHP Annual Meeting
Regulation Of Plasmacytoid Dendritic Cells By Prostaglandin E2
Alice E. Wiedeman¹ and Keith B. Elkon², ¹Immunology, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Plasmacytoid dendritic cells (pDCs) constitute a rare blood cell subset exquisitely attuned for production of large quantities of interferon-alpha (IFN-α), and these cells have…
Abstract Number: 645 • 2013 ACR/ARHP Annual Meeting
Transcript Profiling Of Blood and Kidney Biopsies From Chinese Patients With Lupus Nephritis Reveals Concordant Activation Of Type I IFN Signaling In The Blood and Kidney, Reduced B Cell Presence In The Blood, and Increased Macrophages In The Kidney
Zheng Liu¹, Chris, A. Morehouse¹, Xinfang Huang², Philip Brohawn¹, Nan Shen², Yihong Yao¹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Dept of Rheumatology, Shanghai Ren Ji Hospital, Shanghai, China
Background/Purpose: Up-regulated expression of type I interferon-regulated genes has consistently been observed within the peripheral blood in a large proportion of patients with active systemic…
Abstract Number: 167 • 2013 ACR/ARHP Annual Meeting
Association Of Functional Polymorphisms In IRF2 With Systemic Lupus Erythematosus In a Japanese Population
Aya Kawasaki¹, Hiroshi Furukawa², Nao Nishida³, Eiji Warabi⁴, Yuya Kondo⁵, Satoshi Ito⁶, Isao Matsumoto⁷, Makio Kusaoi⁸, Akiko Suda⁹, Shouhei Nagaoka¹⁰, Keigo Setoguchi¹¹, Tatsuo Nagai¹², Shunsei Hirohata¹³, Katsushi Tokunaga¹⁴, Yoshinari Takasaki¹⁵, Hiroshi Hashimoto¹⁶, Takayuki Sumida⁵, Shigeto Tohma² and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ³Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan, ⁴Environmental Molecular Biology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁵Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁶Niigata Rheumatic Center, Shibata, Japan, ⁷Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan, ⁸Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan, ⁹Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ¹⁰Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, ¹¹Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, ¹²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ¹³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ¹⁴Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ¹⁵Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁶Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Interferon regulatory factor (IRF) families are transcription factors involved in type I interferon (IFN) pathway. Recent genetic studies identified association of IRF family genes,…
Abstract Number: 2890 • 2013 ACR/ARHP Annual Meeting
Novel Selective Inhibitors Of Nuclear Export (SINE) Decrease Type I Interferon Activation and Deplete Autoreactive Plasma Cells In The Kidney In Murine Lupus
Teresa Owen¹, Javier Rangel-Moreno², Boris Klebanov³, Yosef Landesman³, Michael Kauffman³, Sharon Shacham³ and Jennifer H. Anolik⁴, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ³Karyopharm Therapeutics Inc., Natick, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: There is great interest in developing new treatment approaches for SLE, but the biologic therapies under investigation over the past several years have yielded…
Abstract Number: 2810 • 2013 ACR/ARHP Annual Meeting
Follow-Up Testing Of Interferon-Gamma Release Assays For The Diagnosis Of Hidden Tuberculosis Infection In Patients Receiving Tumor Necrosis Factor Alpha Antagonists
Chan-Nam Son¹, Tae-Hwan Kim², Il-Hoon Sung³, Jae-Bum Jun² and Dae-Hyun Yoo², ¹Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Orthopaedic surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Anti-tumor necrosis factor alpha (Anti-TNFα) therapy is often used in patients with rheumatic diseases who do not respond to conventional treatment. Risk of tuberculosis…
Abstract Number: 2347 • 2013 ACR/ARHP Annual Meeting
Functional Single Nucleotide Polymorphisms In The Interferon-γ and The NLRP3 (Cryopyrin) Genes Associated With Anti-TNF Response In Danish Rheumatoid Arthritis Patients
Jacob Sode^1,2,3, Niels H. H. Heegaard⁴, Henning Locht², Ulla Vogel⁵, Steffen Bank^6,7, Merete Lund Hetland^8,9 and Vibeke Andersen^3,7,10,11, ¹Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ⁵National Research Centre for the Working Environment, Copenhagen, Denmark, ⁶Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, ⁷Medical Department, Viborg Regional Hospital, Viborg, Denmark, ⁸The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ¹⁰Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, ¹¹Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark
Background/Purpose: Most patients with rheumatoid arthritis (RA) benefit from tumor necrosis factor-a blocking treatment (anti-TNF). About 1/3, however, do not respond to this costly and…
Abstract Number: 2057 • 2013 ACR/ARHP Annual Meeting
Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – The RIM (Rituximab in Myositis) Trial
Ann M. Reed¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla³, Helen Khun², Rohit Aggarwal⁴, Dana P. Ascherman⁵, Marc C. Levesque⁶ and Chester V. Oddis⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The aim of this study was to examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies (autoAbs) as biomarkers of…
Abstract Number: 1754 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Peg-IFNa/Ribavirin/Protease Inhibitor Combination In 34 Patients With HCV-Mixed Cryoglobulinemia Vasculitis
David Saadoun¹, Stanislas Pol², Vincent Thibault³, Gilles Pialoux⁴, François Blanc⁵, Lucile Musset⁶, Alexandre Karras⁷, Olivier Decaux⁸, Jean-Marc Ziza⁹, Olivier Lambotte¹⁰ and Patrice Cacoub Sr.¹¹, ¹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²Hepatology, Cochin Hospital, Paris, France, ³Virology, Pitié-Salpétrière, Paris, France, ⁴hôpital Tenon, Paris, France, ⁵hôpital Montpellier, Montpellier, France, ⁶Laboratoire d'immunochimie, Pitié- Salpêtrière, Paris, France, ⁷Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Refferal center for bone and joint infections, Croix Saint Simon Hospital, Paris, France, ¹⁰Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, ¹¹Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: The standard of care treatment of patients presenting a HCV-mixed cryoglobulinemia (MC) vasculitis includes Peg-IFNaplus Ribavirin, w/wo Rituximab. Thirty to 40% of patients are…
Abstract Number: 1731 • 2013 ACR/ARHP Annual Meeting
Treatment Of Innate Immune Arthritis With a Toll-Like Receptor 7 Agonist Requires Type I Interferon
Maripat Corr¹, Tomoko Hayashi², Dennis A. Carson³, Howard Cottam⁴ and Joshua Yang³, ¹Medicine, Univ of California-San Diego, La Jolla, CA, ²Medicine, UCSD School of Medicine, La Jolla, CA, ³UCSD School of Medicine, La Jolla, CA, ⁴ucsd School of Medicine, La Jolla, CA
Background/Purpose: We previously demonstrated that repeated administration of the low molecular weight Toll-like receptor (TLR) 7 agonist (1V136) substantially reduces arthritic inflammation in mice. Here…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].